Company
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 22 of 55
Archive
UK – Strong manufacturing PMI data released this morning with growth in production and new orders among the strongest in the past seven years leading to a solid increase in employment. Further loosening of COVID-19 restrictions at home and
The pharma giant is “becoming a cleaner story for investors to own”, analysts said
The firm said it is the most significant advancement in the treatment of chronic kidney disease in more than 20 years
AstraZeneca was in court defending itself this week after the EU launched legal action
The pharma giant said the second half will see a boost in performance
Archive
Footsie finished Friday ahead by around eight points, or 0.12%, at 6,969,
Archive
FTSE 100 giants AstraZeneca and Barclays are set to declare first-quarter results on Friday
The EU Commission has sued the pharma giant over COVID-19 vaccine deliveries
The offer will consist of 6.5mln American Depositary Shares (ADS) priced at US$16-18 each
All 27 states backed the legal challenge, which started last Friday
A Dutch official said the doses will be left behind once the country receives supplies from other manufacturers
An EMA committee recommended conditional marketing authorisation for both selumetinib and tagrisso
The first dose of a COVID-19 vaccine was enough to push infections down by 65%
Archive
Gold - $1,793/oz – prices break out as Bitcoin melts down and on prospects for further stimulus funding in India and other emerging markets Rise in Indian Covid cases creates new concern for central bankers and policymakers as Delhi locksdo
The pharma giant should tread carefully, analysts said, as the EU is a vital part of its business
The pharma firm agreed to acquire the rare disease specialist in December last year in a deal worth US$39bn
Cases were more common after COVID-19 than in any of the comparison groups, with 30% of these cases occurring in the under 30s
Mixing vaccines could allow for a more flexible rollout and to make up for shortfalls of doses, researchers said
The bloc is planning to focus on mRNA-based vaccines, such as those produced by Pfizer and Moderna
More than a third of the world's lung cancer patients are in China
